Cited 12 times in

A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer

Authors
 K H Park  ;  S Lee  ;  J H Park  ;  S Y Kang  ;  H Y Kim  ;  I H Park  ;  Y H Park  ;  Y H Im  ;  H J Lee  ;  S Park  ;  S I Lee  ;  K H Jung  ;  Y S Kim  ;  Jae Hong Seo 
Citation
 SUPPORTIVE CARE IN CANCER, Vol.25(2) : 505-511, 2017-02 
Journal Title
SUPPORTIVE CARE IN CANCER
ISSN
 0941-4355 
Issue Date
2017-02
MeSH
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols / administration & dosage ; Antineoplastic Combined Chemotherapy Protocols / adverse effects ; Breast Neoplasms / drug therapy ; Chemotherapy-Induced Febrile Neutropenia / drug therapy* ; Chemotherapy-Induced Febrile Neutropenia / etiology ; Chemotherapy-Induced Febrile Neutropenia / prevention & control ; Cyclophosphamide / administration & dosage ; Docetaxel ; Doxorubicin / administration & dosage ; Drug Administration Schedule ; Female ; Filgrastim / administration & dosage* ; Filgrastim / adverse effects ; Granulocyte Colony-Stimulating Factor / administration & dosage* ; Granulocyte Colony-Stimulating Factor / adverse effects ; Humans ; Injections, Subcutaneous ; Middle Aged ; Polyethylene Glycols / administration & dosage* ; Polyethylene Glycols / adverse effects ; Taxoids / administration & dosage
Keywords
Breast cancer ; Neutropenia ; Pegylated G-CSF ; TAC chemotherapy
Abstract
Purpose: This multi-center, randomized, phase III study was conducted to demonstrate the non-inferiority of DA-3031 compared with daily filgrastim in patients during the first cycle of chemotherapy for breast cancer in terms of the duration of severe neutropenia (DSN).

Methods: Seventy-four patients with breast cancer who were receiving combination chemotherapy with docetaxel, doxorubicin, and cyclophosphamide (TAC) were enrolled. All participants were randomized to receive either daily subcutaneous injections of filgrastim 100 μg/m2/day for up to 10 days or a single subcutaneous injection of DA-3031 at fixed doses of 6 mg on day 2 of each chemotherapy cycle.

Results: The mean duration of grade 4 (G4) neutropenia in cycle 1 was 2.08 ± 0.85 days for the filgrastim group and 2.28 ± 1.14 days for the DA-3031 group. The difference between groups was 0.2 ± 1.10 days (95 % confidence interval (CI) = -0.26, 0.66), which supported non-inferiority. No statistically significant differences were observed in nadir absolute neutrophil count (ANC) (154.34/mm3 and 161.75/mm3 for the filgrastim and DA-3031 groups, respectively; P = 0.8414) or in time to ANC recovery (10.03 ± 0.75 and 9.83 ± 1.56 days in the filgrastim and DA-3031 groups, respectively; P = 0.0611) during cycle 1. Serious AEs occurred in six (15.8 %) patients receiving filgrastim and in ten (27.8 %) patients receiving DA-3031; however, none was determined to be related to the study drug.

Conclusions: DA-3031 and daily filgrastim are similar in regard to DSN and safety in breast cancer patients receiving TAC chemotherapy.
Full Text
https://link.springer.com/article/10.1007/s00520-016-3429-2
DOI
10.1007/s00520-016-3429-2
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/195899
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links